Pemetrexed and Methotrexate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pemetrexed (pemetrexed) and Methotrexate (methotrexate sodium). Common drug interactions include lymphoproliferative disorder among females and malignant neoplasm progression among males.

The phase IV clinical study analyzes what interactions people have when they take Pemetrexed and Methotrexate. It is created by eHealthMe based on reports of 79 people who take the same drugs from the FDA, and is updated regularly.

What is Pemetrexed?

Pemetrexed has active ingredients of pemetrexed. eHealthMe is studying from 17,491 Pemetrexed users. Check the latest studies of Pemetrexed.

What is Methotrexate?

Methotrexate has active ingredients of methotrexate sodium. It is often used in rheumatoid arthritis. eHealthMe is studying from 604,312 Methotrexate users. Check the latest studies of Methotrexate.



On Jul, 09, 2026

79 people who take Pemetrexed and Methotrexate together, and have interactions are studied.

Pemetrexed and Methotrexate drug interactions.

What are the common drug interactions of Pemetrexed and Methotrexate, by gender? *:

female:

  1. Lymphoproliferative disorder (a medical condition in which the immune system makes too many white blood cells)
  2. Monocyte count decreased
  3. Multi-organ failure (multisystem organ failure)
  4. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  5. Portal vein thrombosis (venous thrombosis affecting the hepatic portal vein)
  6. Sepsis (a severe blood infection that can lead to organ failure and death)
  7. Septic shock (shock due to blood infection)
  8. Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
  9. Urinary tract infection
  10. Malignant neoplasm progression (cancer tumour came back)

male:

  1. Malignant neoplasm progression (cancer tumour came back)
  2. Asthenia (weakness)
  3. Nephropathy toxic (damage to kidney due to toxins)
  4. Optic neuritis (optic nerve inflammation)
  5. Renal impairment (severely reduced kidney function)
  6. Visual acuity reduced (reduced clearness of vision)
  7. Aplasia (defective development or congenital absence of an organ or tissue)
  8. Death
  9. Infection
  10. Bone marrow failure

What are the common drug interactions of Pemetrexed and Methotrexate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Bone marrow failure
  2. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  3. Liver injury
  4. Hepatotoxicity (chemical-driven liver damage)
  5. Hypertriglyceridaemia (excess of triglycerides in the blood)
  6. Lung adenocarcinoma (a form of non-small cell lung cancer)
  7. Lung infection
  8. Nosocomial infection (infection from hospital)

50-59:

  1. Disease progression
  2. Death
  3. Drug ineffective
  4. Acne (skin problems that cause pimples)
  5. Metastases to meninges (cancer spreads to meninges)
  6. Mucosal inflammation (infection of mucous membrane)
  7. Nasal inflammation (inflammation of nose)

60+:

  1. Malignant neoplasm progression (cancer tumour came back)
  2. Pneumonitis (inflammation of the walls of the alveoli in the lungs)
  3. Asthenia (weakness)
  4. Bronchostenosis (narrowing of a bronchial tube by scarring or other stricture)
  5. Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs)
  6. Enterococcus test positive
  7. Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)
  8. Staphylococcus test positive
  9. Cushing's syndrome (obesity, a rounded face, increased fat)
  10. Lung cancer metastatic (lung cancer spreads to other parts)

What are the existing conditions these people have? *

  1. Adrenocortical Carcinoma (adrenal cortex cancer): 11 people, 13.92%
  2. Lung Cancer - Non-Small Cell (lung cancer): 10 people, 12.66%
  3. Lung Adenocarcinoma (a form of non-small cell lung cancer): 10 people, 12.66%
  4. Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 7 people, 8.86%
  5. Neoplasm Malignant (cancer tumour): 6 people, 7.59%
  6. Metastases To Lung (cancer spreads to lung): 5 people, 6.33%
  7. High Blood Pressure: 5 people, 6.33%
  8. Optic Neuritis (optic nerve inflammation): 4 people, 5.06%
  9. Metastases To Central Nervous System (cancer spreads to central nervous system): 4 people, 5.06%
  10. Mesothelioma (rare type of cancer that occurs in the thin layer of cells lining the body's internal organs, known as the mesothelium): 4 people, 5.06%

* Approximation only. Some reports may have incomplete information.

Do you take Pemetrexed and Methotrexate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Pemetrexed and Methotrexate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Pemetrexed:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Methotrexate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pemetrexed and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methotrexate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on pemetrexed and methotrexate sodium (the active ingredients of Pemetrexed and Methotrexate, respectively), and Pemetrexed and Methotrexate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: